Neumora Therapeutics Inc (NMRA)

$3.45 +0.06 (1.77%)
Market Cap 566.43M
Revenue (ttm) 0.00
Net Income (ttm) -243.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 499,600
Avg Vol 1,817,642
Day's Range N/A - N/A
Shares Out 167.09M
Stochastic %K 83%
Beta 3.20
Analysts Sell
Price Target $9.14

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 760 0900
Address:
490 Arsenal Way, Suite 200, Watertown, United States
Keystone1
Keystone1 Feb. 23 at 8:34 PM
$NMRA Just added 5,000 more here. Looking strong in a bad market!
0 · Reply
InvestorCG
InvestorCG Feb. 23 at 4:40 PM
$NMRA $NVO next generation obesity drug was not impressive. I have them as the number 1 potential acquiror of us.
2 · Reply
Mr_GA
Mr_GA Feb. 23 at 3:43 PM
$NMRA Holding up quite well today. IMO
1 · Reply
AlphaDeskWealth
AlphaDeskWealth Feb. 22 at 9:32 PM
$NMRA Invus Public Equities and Avicenna Life Sci Master Fund disclosed a combined 5.4% stake (8,997,822 shares). Invus is a global investment firm known for its long-term concentrated value approach in the life sciences sector. Raymond Debbane (CEO of Invus) is listed as the beneficial owner. Invus taking a major stake at this stage suggests high conviction in Neumora's late-stage pipeline. Unlike debt flippers Invus typically maintains positions through major clinical milestones. Current ownership: Amgen Inc. 21.0% ARCH Venture Partners 20.7% Paul Berns (CEO) 5.1% Softbank Group 3.8% 52-60% of the company is now controlled by institutional Whales and top-tier funds like Invus which are actively positioning themselves for the next phase of growth. The real Free Float is estimated at only 34.68%, or about 57.9 million shares with Short interest currently 5.63M (10%) With this low float If demand spikes during the Q2 Navacaprant readout the lack of supply will lead to large price gapping.
1 · Reply
Mr_GA
Mr_GA Feb. 22 at 5:29 AM
$NMRA https://neumoratx.com/pipeline/
0 · Reply
Keystone1
Keystone1 Feb. 21 at 8:54 PM
$NMRA Great info thanks! Exciting times for shareholders. Thinking about buying more.
0 · Reply
InvestorCG
InvestorCG Feb. 20 at 5:17 PM
$NMRA Anyone look at $NMRA Feb presentation slides and see that we actually have 2 Obesity products in the queue. One is "Undisclosed". This is another catalyst that we should find out about shortly.
0 · Reply
InvestorCG
InvestorCG Feb. 20 at 5:13 PM
$NMRA Low volume fade Friday. I'm sure there are institutions that have become less aggressive here waiting to see if K2 will afford them the opportunity for cheapies.
0 · Reply
tazzcrazy
tazzcrazy Feb. 20 at 3:27 PM
$NMRA 🚀 🚀 🚀
0 · Reply
Only_Bulls
Only_Bulls Feb. 20 at 12:59 AM
$NMRA $NMRA 🚨🔥 WHO’S BEEN BUYING?! 13G JUST DROPPED. INVUS (big-boy fund complex) just filed a Schedule 13G showing they’re ~5%+ owners of NMRA. That’s not retail noise — that’s institutional size. • Invus Public Equities: 8,172,814 shares (~4.9%) • Control person listed: ~8,997,822 shares (~5.4%) This is exactly what the tape has been screaming lately: quiet accumulation → float gets tighter → price starts walking up. Retail sees “no news”… meanwhile the sharks are filing 5% ownership disclosures. 🤝💎 If the Street keeps rolling out upgrades/targets and momentum stays hot, this can get repriced FAST. Not advice — just saying: institutions don’t file 13Gs for fun. 🚀🧨
0 · Reply
Latest News on NMRA
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

Feb 17, 2026, 2:32 PM EST - 6 days ago

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 19 days ago

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Jan 5, 2026, 1:28 PM EST - 7 weeks ago

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Jan 5, 2026, 6:35 AM EST - 7 weeks ago

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

Jan 5, 2026, 6:30 AM EST - 7 weeks ago

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

Dec 1, 2025, 1:45 PM EST - 3 months ago

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 7:00 AM EST - 3 months ago

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Participate in Upcoming Conferences in November

Nov 3, 2025, 7:00 AM EST - 4 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

Oct 27, 2025, 1:57 PM EDT - 4 months ago

Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Oct 27, 2025, 6:30 AM EDT - 4 months ago

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Neumora Therapeutics to Host Virtual R&D Day on October 27

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27

Neumora Therapeutics to Participate in Upcoming Conferences in September

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in September

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:41 AM EDT - 7 months ago

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 7:00 AM EDT - 7 months ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:18 PM EDT - 10 months ago

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 10 months ago

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 7:00 AM EDT - 10 months ago

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Apr 4, 2025, 4:05 PM EDT - 11 months ago

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 30, 2025, 4:00 PM EDT - 11 months ago

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

Mar 27, 2025, 5:45 AM EDT - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 26, 2025, 2:19 AM EDT - 11 months ago

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 15, 2025, 9:29 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 13, 2025, 10:19 AM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

Mar 6, 2025, 12:17 PM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:37 AM EST - 1 year ago

Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Keystone1
Keystone1 Feb. 23 at 8:34 PM
$NMRA Just added 5,000 more here. Looking strong in a bad market!
0 · Reply
InvestorCG
InvestorCG Feb. 23 at 4:40 PM
$NMRA $NVO next generation obesity drug was not impressive. I have them as the number 1 potential acquiror of us.
2 · Reply
Mr_GA
Mr_GA Feb. 23 at 3:43 PM
$NMRA Holding up quite well today. IMO
1 · Reply
AlphaDeskWealth
AlphaDeskWealth Feb. 22 at 9:32 PM
$NMRA Invus Public Equities and Avicenna Life Sci Master Fund disclosed a combined 5.4% stake (8,997,822 shares). Invus is a global investment firm known for its long-term concentrated value approach in the life sciences sector. Raymond Debbane (CEO of Invus) is listed as the beneficial owner. Invus taking a major stake at this stage suggests high conviction in Neumora's late-stage pipeline. Unlike debt flippers Invus typically maintains positions through major clinical milestones. Current ownership: Amgen Inc. 21.0% ARCH Venture Partners 20.7% Paul Berns (CEO) 5.1% Softbank Group 3.8% 52-60% of the company is now controlled by institutional Whales and top-tier funds like Invus which are actively positioning themselves for the next phase of growth. The real Free Float is estimated at only 34.68%, or about 57.9 million shares with Short interest currently 5.63M (10%) With this low float If demand spikes during the Q2 Navacaprant readout the lack of supply will lead to large price gapping.
1 · Reply
Mr_GA
Mr_GA Feb. 22 at 5:29 AM
$NMRA https://neumoratx.com/pipeline/
0 · Reply
Keystone1
Keystone1 Feb. 21 at 8:54 PM
$NMRA Great info thanks! Exciting times for shareholders. Thinking about buying more.
0 · Reply
InvestorCG
InvestorCG Feb. 20 at 5:17 PM
$NMRA Anyone look at $NMRA Feb presentation slides and see that we actually have 2 Obesity products in the queue. One is "Undisclosed". This is another catalyst that we should find out about shortly.
0 · Reply
InvestorCG
InvestorCG Feb. 20 at 5:13 PM
$NMRA Low volume fade Friday. I'm sure there are institutions that have become less aggressive here waiting to see if K2 will afford them the opportunity for cheapies.
0 · Reply
tazzcrazy
tazzcrazy Feb. 20 at 3:27 PM
$NMRA 🚀 🚀 🚀
0 · Reply
Only_Bulls
Only_Bulls Feb. 20 at 12:59 AM
$NMRA $NMRA 🚨🔥 WHO’S BEEN BUYING?! 13G JUST DROPPED. INVUS (big-boy fund complex) just filed a Schedule 13G showing they’re ~5%+ owners of NMRA. That’s not retail noise — that’s institutional size. • Invus Public Equities: 8,172,814 shares (~4.9%) • Control person listed: ~8,997,822 shares (~5.4%) This is exactly what the tape has been screaming lately: quiet accumulation → float gets tighter → price starts walking up. Retail sees “no news”… meanwhile the sharks are filing 5% ownership disclosures. 🤝💎 If the Street keeps rolling out upgrades/targets and momentum stays hot, this can get repriced FAST. Not advice — just saying: institutions don’t file 13Gs for fun. 🚀🧨
0 · Reply
InvestorCG
InvestorCG Feb. 19 at 9:56 PM
$NMRA new 13G out. This one is 100% positive. Looks like Invus bought 4-5 mil shares here. They were at 3-4 mil now control almost 9 mil shares. https://ir.neumoratx.com/node/8246/html
0 · Reply
InvestorCG
InvestorCG Feb. 19 at 3:43 PM
$NMRA We were due for a pullback, and I don't know if its coincidence, but K2 is the rake IMO. Consolidation period boys and gals.
1 · Reply
Xmandingo
Xmandingo Feb. 19 at 1:18 PM
$NMRA Today!!
0 · Reply
AnomalyDetective
AnomalyDetective Feb. 19 at 1:08 PM
🔴 New Week 9 MDA breakout picks out for members released after the close today despite negative MG signals. https://seekingalpha.com/mp/1201-value-momentum-breakouts 💥Week 8 MDA picks up +4.21% with two out of 4 picks up higher than 10% through Thursday including $NMRA 💥 Extending the count to 357 weeks with one or more of the weekly picks gaining over 10% in less than a week and average annual cumulative returns over 4x the $SPY #SPX $QQQ 💥 $WMT -3.05% beat on earnings but guided lower for sales and earnings in sharp market declines premarket for the largest stock report earning this week. $NVDA reports next week. 💥 Long term portfolios beating the major indices again this year led by the January Dividend portfolio +12.37% YTD and up +13.72% adjusted for #dividends. Credit: http://vmbreakouts.com @vmbreakouts
0 · Reply
SPuffet
SPuffet Feb. 18 at 8:44 PM
$NMRA 4 the last 15 mins? Just joking
0 · Reply
InvestorCG
InvestorCG Feb. 18 at 2:58 PM
$NMRA What is interesting here is the institutional buying !!! https://www.marketbeat.com/instant-alerts/neumora-therapeutics-nasdaqnmra-hits-new-12-month-high-following-analyst-upgrade-2026-02-18/
1 · Reply
SPuffet
SPuffet Feb. 18 at 2:43 PM
$NMRA expected pull back; if it gets positive, another gap up imminent
0 · Reply
Mr_GA
Mr_GA Feb. 18 at 4:30 AM
$NMRA Keep pushing, maybe get there by the end of this month?
0 · Reply
Mr_GA
Mr_GA Feb. 17 at 11:14 PM
$NMRA New 52 week high today.
0 · Reply
AnomalyDetective
AnomalyDetective Feb. 17 at 7:33 PM
$NMRA the first of the four Week 8 MDA breakout picks to clear 10% gains through Tuesday. Portfolio is up +4.24% extending the count of at least one pick breaking 10% in less than a week to 357 weeks in both positive/negative Market MG signals. @vmbreakouts http://vmbreakouts.com
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:25 PM
$NMRA $CHOW $ESOA $GLE \\
0 · Reply
Xmandingo
Xmandingo Feb. 17 at 5:46 PM
$NMRA
0 · Reply